Folio Biosciences and Conversant Bio have merged to create the life science industry’s premier provider of research services and biospecimen solutions, particularly FFPE tissue and blood, supported by comprehensive laboratory and analytic services.

1. General Capabilities Presentation
July 2018

2. Folio + Conversant Bio Merger
Folio Biosciences and Conversant Bio have merged
to create the life science industry’s premier provider
of research services and biospecimen solutions,
particularly FFPE tissue and blood, supported by
comprehensive laboratory and analytic services.
2

3. LEADER IN BIOSPECIMEN SOLUTIONS
Specialized Team
125+ Professionals, including Cell Biology, Pathology, Medical Doctors
Clinical Experience
10,000+ Studies Completed in Oncology, Immunology, Neurology & Normals
Quality Systems
3

4. Biosample Solutions
Research
Success
Expanded Research Solutions
4
Histo-
Path
Tissues
Sourcing
& Sites
In-vitro,
Flow
Fluids - Healthy, Disease
Tissues - Disease
In-house Leukapheresis
Cell Biology Solutions
Flow
Culture
Sequencing
Cell Isolations
Tissue/Tumor Dissociations
Pathology Solutions
IHC / Staining
mRNA, miRNA, in situ
Clinical/ Experimental Path
High-res Imaging
Sourcing Solutions
Custom / Complex Procurement
Global Procurement
Autopsy

5. Normals /
Other
Specialized for Biopharma & Diagnostics
CancerAutoimmune Neurology
Lupus
Rheumatoid Arthritis
Crohn’s
UC
etc.
Breast
Lung
Colon
Prostate
etc.
Normal Donor
Dermatology
Transplantation
etc.
5
Alzheimer's
Parkinson's
ALS
Multiple Sclerosis
etc.
Broader Disease Focus

6. LARGE, GLOBAL CLINICAL SITE NETWORK
125+ Clinical Sites
& Growing
6
● 1,000+ Participating PIs
● Access to deep clinical data
● Embedded Site Employees
● Broad Consent for Genomic Studies
● Oncology, Immunology, Neurology,
Dermatology, GI, Normals

7. 7
Biospecimen Solutions and
Research Services

8. 8
FFPE TISSUE REPOSITORY
Expanded Pathology Verified Cohorts Ready to Ship
● Non-Small Cell Lung Carcinoma – 2000+ US cases
● Breast Cancer – 1500+ US cases, including 400+ TNBCs
● Colorectal Cancer – 1300+ US cases, some MSI-H screened
● Hepatocellular Carcinoma – 500+ cases
● Gastric Cancer – 400+ cases
● Idiopathic Pulmonary Fibrosis – 100+ US Cases
● 300+ cases for each of the following indications:
○ Head and Neck, Prostate, Pancreatic, Bladder, Brain, Endometrial

9. 9
CENTRAL PATHOLOGY LAB - R&D/CLINICAL TRIALS
CLIA Certified Lab, Board Certified Pathologists
○ Immunohistochemistry staining
○ In situ hybridization for transcripts and miRNA
○ Customized histological staining services
○ High-resolution Aperio scanning
○ Pathology evaluation + consultation services
○ Clinical Trial Central Lab

10. 10
CLINICAL NETWORK & BIOFLUIDS
Cohorts, Tubes, and Data Designed for You
● Expanded Cancer Cohorts: IO Treated, Known Mutation, Late Stage
○ Base Demographic, Primary Diagnosis, Clinical History, Treatment
○ Physician Notes, including follow up data
● Expanded Inflammatory Network: Rheumatology, Dermatology, GI
○ SLE, RA, Psoriasis, Crohn’s, Ulcerative Colitis, etc.
● Custom Processing
○ ctDNA high speed double spin protocol available
● Flow + Cell Sorting
○ Flow Readouts tied to Unique Patient and Sample ID, Negative Cell Sorting
● Longitudinal Draws, Other Matched Biofluids (Urine, Saliva)

11. 11
NORMAL DONOR NETWORK
Custom Collection and Processing of Blood and Biofluids
○ Large and diverse network of donors available (> 900)
○ Longitudinal & time matched collections available
○ NGS characterized for HLA-A (includes HLA-A*02:01:01G)
○ High quality samples - ISO 9001 validation
○ Subscription plans available for recurring orders
○ All donors are virus tested (HIV, HBV, HCV)

12. 12
NORMAL ISOLATED IMMUNE CELLS
A Reliable Partner for Quality/Custom Isolations
○ Consistent quality (viability and purity >85-95%)
○ Custom isolations, expansions, and flow cytometry
characterization available
○ Recallable donors for longitudinal collections
○ Fast accrual timelines for custom collections
○ Customizable project logistics (screening, recurring orders,
scheduling deliveries, etc)

13. 13
DISSOCIATED TUMOR CELLS (DTCs)
A Viable Alternative to Fresh Tissue
● Key Points
○ Custom Proprietary Indication by Indication Dissociation Protocol
○ DTCs contain high percentages of viable cells both pre-freeze
(81.3%) and post-thaw (69.7%)
○ DTCs consist of the full cellular composition of the tumor
microenvironment (tumor, immune and support cells)
○ All lymphoid subsets can be found in dissociated tumor cells (T
cells, B cells and NK cells), and Myeloid Cells

14. 14
CELL SERVICES
Currently Available Research Applications
Flow Cytometry Cell Culture Sequencing Cell Isolations Next-Generation
Dissociations

15. 15
Please consider us a resource.
sales@folioconversant.com